In Vitro Chemoresponse Analysis of Cervical Cancer Patient Specimens

Grigsby, Perry W.; Gan, Christine; Tillmanns, Todd; Priore, Giuseppe Del

doi:10.1097/igc.0000000000000186

Cited by 3 publications

(2 citation statements)

References 63 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Multiple chemotherapy agents were tested and reported in that initial study, but there was no data presented regarding patient treatment or outcome. The study did demonstrate that the in vitro response rates of primary cervix cancer biopsy specimens to single agent cisplatin were 48% for adenocarcinoma and 53% for squamous cell cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro chemoresponse to cisplatin and outcomes in cervical cancer

Grigsby¹,

Zighelboim²,

Powell³

et al. 2013

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Objective Aim of this study was to report clinical outcomes of cervical cancer patients treated with weekly cisplatin chemo-radiation therapy (chemoRT) stratified by pre-treatment cisplatin in vitro chemosensitivity. Methods This was a retrospective analysis of patients with cervical cancer seen at our institution between May 2009 and August 2011. Patients underwent pre-treatment in vitro chemoresponse testing (Precision Therapeutics, Inc.) and were treated with concurrent weekly cisplatin chemoRT. The study consisted of 33 patients with FIGO tumor stages Ib2 to IIIb. Pre-treatment cisplatin chemoresponse of individual patient tumors was determined from chemoresponse dose response curves and scored as responsive (R), intermediate response (IR), or nonresponsive (NR). Results There were 28 patients with squamous cell carcinoma and 5 with adenocarcinoma. Cisplatin chemosensitivity was R and IR in 18 patient specimens and NR in 15. The 2-year recurrence-free survivals (RFS) were 87% for patients whose specimens tested R+ IR to cisplatin compared to 58% for those whose specimens were NR (p = 0.036). The 2-year RFS was 86% for the R + IR group compared to 46% for the NR group for patients with tumors that were squamous cell histology (p = 0.009). Stepwise proportional hazards modeling for RFS demonstrated that chemoresponsiveness to cisplatin (p = 0.029) and FDG-PET lymph node status (p = 0.011) were the only independent predictors of RFS for patients with squamous cell histology. Conclusion Pre-treatment in vitro cisplatin chemoresponse testing of cervix cancer biopsies was technically feasible and prognostic of RFS in patients treated with weekly cisplatin chemoRT.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The results of a recent study of in vitro chemoresponse in 273 cervix cancer patient specimens demonstrated the feasibility of performing the in vitro chemoresponsiveness assay and that there is variability in chemoresponse among patients. 9 …”

Section: Introductionmentioning

confidence: 99%